Valiant Organics Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹976 Cr
- P/E
- 17.46
- ROE
- 4.00%
- PEG
- -0.63
- Price to sales
- 1.07
- Debt to equity
- 0.33
- 52W high / low
- ₹497 / ₹198
- Sales growth (5Y)
- 5.16%
- EBITDA margin
- 13.45%
- Net profit margin
- 3.68%
- Promoter holding
- 37.89%
- Sales (last year)
- ₹913 Cr
Guidance scorecard · Q2 FY27 call
What Valiant Organics's management guided
and where it ranks in Chemicals & Petrochemicals
RevenueQ3 FY24 call
40%+- FY25 revenue expected in the range of INR 900-1000 crores, with conservative estimates due to current market conditions.
- Growth of approximately 40% anticipated in FY25 driven by volume improvement in PAP and new Pharma Intermediates and chlorophenol products.
- Incremental revenue of around INR 200 crores expected from PAP at full capacity (~600-700 tons/month targeted by year-end).
- Pharma Intermediates expected to contribute approximately INR 70-80 crores, with launch of eight new products planned early FY25.
- OAP products likely to add INR 20-30 crores.
- Capacity expansions have increased overall production capabilities significantly since 2020, with about 2000 MT added annually excluding PAP.
2 more points from Valiant Organics's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY24 call
Up 2%+See what Valiant Organics said on margins — free account, 30 seconds.
CapexQ3 FY24 call
None planned- For FY25, Valiant Organics does not plan any large or significant CapEx, only standard maintenance CapEx of around INR 30-40 crores.
- Any major CapEx decisions will be considered based on how the current year unfolds, potentially planned in the second half of the year for subsequent years.
- No immediate major capital investment is planned until market conditions stabilize, especially given the current pricing pressures.
2 more points from Valiant Organics's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY24 call
See what Valiant Organics said on fundraising — free account, 30 seconds.
Order bookQ3 FY24 call
- There has been subdued demand and pressure on pricing due to global slowdown and China dumping.
- PAP (Paracetamol) sales averaged 119 MT per month initially, with a surge to 370 MT in December, indicating improving demand.
- Management expects FY25 to be significantly better due to volume growth in PAP and new Pharma Intermediate projects.
2 more points from Valiant Organics's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Valiant Organics latest results (Sep 2026)
Revenue
₹304 Cr
+93% YoY
Net profit
₹17 Cr
+183% YoY
Operating margin
13%
EPS
₹6.17
Valiant Organics shareholding (Sep 2026)
Promoters
37.89%
+0.02 pp QoQ
FIIs
0.44%
+0.23 pp QoQ
DIIs
0.03%
+0.03 pp QoQ
Public
61.65%
−0.28 pp QoQ
Peers
Chemicals & Petrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹1,778 Cr | 19.8 | |
| 2 | 40%+ | Up 0–2% | ₹262 Cr | 3.4 | |
| 3 | 40%+ | Flat | ₹8,439 Cr | 208.8 | |
| 4 | 40%+ | Flat | ₹2,302 Cr | 26.3 | |
| 5 | 40%+ | Flat | ₹179 Cr | 11.8 | |
| 6 | 40%+ | Flat | ₹154 Cr | 16.9 |
Sign up free to see every company in the sector ranking and track Valiant Organics.
Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals rankingFinancials of Valiant Organics
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Valiant Organics
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 37.90% | 37.77% | 37.77% | 37.77% | 37.73% | 37.91% | 37.91% | 37.91% | 37.89% | 37.89% | 37.87% | 37.89% |
| FIIs + | 0.69% | 1.14% | 1.35% | 1.34% | 0.82% | 0.37% | 0.21% | 0.21% | 0.22% | 0.28% | 0.21% | 0.44% |
| DIIs + | 0.87% | 0.43% | 0.09% | 0.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
| Public + | 60.54% | 60.65% | 60.79% | 60.80% | 61.44% | 61.72% | 61.87% | 61.86% | 61.89% | 61.82% | 61.93% | 61.65% |
| No. of Shareholders | 49,050 | 50,460 | 50,022 | 48,189 | 49,017 | 48,077 | 44,293 | 43,274 | 42,311 | 40,928 | 40,526 | 37,909 |
Financials of Valiant Organics
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 203 | 141 | 177 | 168 | 160 | 187 | 204 | 204 | 157 | 159 | 218 | 232 | 304 |
| YoY Sales growth | -23% | -44% | -35% | -17% | -21% | +32% | +15% | +22% | -2% | -15% | +7% | +13% | +93% |
| Expenses + | 188 | 139 | 179 | 152 | 159 | 172 | 183 | 180 | 136 | 146 | 191 | 190 | 265 |
| Operating Profit | 15 | 3 | -2 | 16 | 1 | 15 | 21 | 25 | 21 | 13 | 26 | 42 | 39 |
| OPM % | 8% | 1.8% | -1.2% | 9% | 0.5% | 8% | 10% | 12% | 13% | 8% | 12% | 18% | 13% |
| Other Income + | 4 | 0 | -7 | 0 | 3 | 6 | 1 | 2 | 0 | 7 | 5 | 11 | 1 |
| Interest | 4 | 4 | 7 | 5 | 8 | 6 | 5 | 6 | 4 | 5 | 3 | 5 | 5 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 6 | -10 | -25 | 2 | -14 | 6 | 7 | 11 | 7 | 6 | 18 | 37 | 25 |
| Tax % | 26% | -20% | -20% | 128% | -9% | 14% | 43% | 26% | 24% | 38% | 10% | 20% | 30% |
| Net Profit + | 5 | -8 | -20 | -1 | -12 | 5 | 4 | 8 | 6 | 4 | 16 | 29 | 17 |
| EPS in Rs | 1.58 | -2.86 | -7.32 | -0.22 | -4.63 | 1.98 | 1.50 | 2.93 | 2.02 | 1.30 | 5.61 | 10.36 | 6.17 |
Financials of Valiant Organics
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 692 | 675 | 755 | 1,153 | 1,052 | 723 | 719 | 739 | 913 |
| Sales growth | -2% | +12% | +53% | -9% | -31% | -1% | +3% | +21% | |
| Expenses + | 511 | 494 | 549 | 948 | 888 | 686 | 665 | 652 | 792 |
| Operating Profit | 181 | 181 | 205 | 205 | 164 | 37 | 53 | 87 | 120 |
| OPM % | 26% | 27% | 27% | 18% | 16% | 5% | 7% | 12% | 13% |
| Other Income + | 8 | 6 | 6 | 7 | 13 | 6 | 9 | 13 | 24 |
| Interest | 4 | 3 | 5 | 6 | 11 | 16 | 24 | 18 | 18 |
| Depreciation | 14 | 16 | 21 | 30 | 29 | 35 | 36 | 40 | 41 |
| Profit before tax | 171 | 168 | 185 | 176 | 137 | -9 | 2 | 42 | 85 |
| Tax % | 29% | 25% | 29% | 27% | 25% | -3% | 260% | 21% | |
| Net Profit + | 121 | 126 | 131 | 128 | 103 | -8 | -3 | 33 | 66 |
| EPS in Rs | 103.65 | 51.00 | 42.19 | 41.72 | 32.45 | -3.04 | -1.34 | 11.86 | 23.44 |
| Dividend Payout % | 6% | 11% | 12% | 8% | 3% | 0% | 0% | 0% |
Financials of Valiant Organics
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 12 | 27 | 27 | 27 | 28 | 28 | 28 | 28 |
| Reserves | 254 | 374 | 475 | 586 | 662 | 702 | 697 | 731 | 778 |
| Borrowings + | 77 | 140 | 209 | 364 | 274 | 257 | 249 | 256 | 259 |
| Other Liabilities + | 112 | 143 | 165 | 216 | 276 | 262 | 209 | 217 | 270 |
| Total Liabilities | 448 | 669 | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,232 | 1,335 |
| Fixed Assets + | 150 | 276 | 510 | 543 | 670 | 643 | 657 | 695 | 678 |
| CWIP | 66 | 129 | 46 | 112 | 71 | 86 | 66 | 21 | 41 |
| Investments | 12 | 23 | 6 | 8 | 41 | 99 | 94 | 151 | 140 |
| Other Assets + | 221 | 241 | 314 | 529 | 457 | 420 | 367 | 365 | 477 |
| Total Assets | 448 | 669 | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,232 | 1,335 |
Financials of Valiant Organics
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 76 | 161 | 113 | -31 | 238 | 84 | 56 | 92 |
| Cash from Investing Activity + | -86 | -184 | -156 | -124 | -143 | -65 | -21 | -86 |
| Cash from Financing Activity + | 1 | 27 | 49 | 167 | -112 | -23 | -32 | -11 |
| Net Cash Flow | -9 | 5 | 5 | 12 | -17 | -4 | 4 | -5 |
| Free Cash Flow | -13 | -44 | -58 | -153 | 108 | 19 | 27 | 59 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 68% | 112% | 78% | 6% | 162% | 238% | 106% | 103% |
Financials of Valiant Organics
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 72 | 76 | 102 | 88 | 106 | 90 | 120 |
| Inventory Days | 44 | 42 | 63 | 54 | 68 | 88 | 71 | 77 |
| Days Payable | 69 | 82 | 93 | 63 | 89 | 159 | 119 | 102 |
| Cash Conversion Cycle | 50 | 32 | 45 | 93 | 67 | 34 | 42 | 96 |
| Working Capital Days | 46 | 20 | -1 | 21 | 11 | -3 | -10 | 0 |
| ROCE % | 39% | 30% | 21% | 14% | 1% | 3% | 5% |
Guidance history
How Valiant Organics's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q3 FY24 call → | 40%+ | Up 2%+ | None planned | — | — |
| Q2 FY24 call → | 10–20% | Down 0–2% | Planned | Planned | — |
| Q1 FY24 call → | Decline | Flat | Planned | Planned | — |
| Q4 FY23 call → | 20–40% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
36 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,947 stocks |
|---|---|---|
| Last 12 months | +19.7% | 70% |
| Last 6 months | +15.5% | 67% |
| Last 3 months | +12.5% | 82% |
The price is 81.1% below its all-time high of ₹1,844.95 (6 Nov 2020). Stocks more than 20% below their peak have their score halved, so 71 became 36.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Valiant Organics: 0.4 × 70 + 0.4 × 67 + 0.2 × 82 = 71, halved to 36 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Valiant Organics: frequently asked questions
What is Valiant Organics share price today?
Valiant Organics last traded at ₹348.2, with a market capitalisation of ₹976 Cr and a P/E ratio of 17.5.
What were Valiant Organics's latest quarterly results?
For the quarter ended Sep 2026, Valiant Organics reported revenue of ₹304 Cr (+93% year on year) and net profit of ₹17 Cr, with an operating margin of 13%.
Is Valiant Organics's profit growing?
Net profit was ₹17 Cr in Sep 2026 against ₹6 Cr in Sep 2025, a change of +183%.
What is Valiant Organics's EPS?
Valiant Organics's earnings per share for the quarter ended Sep 2026 was ₹6.17.
What is the promoter holding in Valiant Organics?
Promoters held 37.89% of Valiant Organics in Sep 2026 (+0.02 pp versus Jun 2026).
How much do FIIs and DIIs hold in Valiant Organics?
In Sep 2026, foreign institutional investors held 0.44% and domestic institutions (including mutual funds) held 0.03% of Valiant Organics.
What is Valiant Organics's ROE and ROCE?
Valiant Organics's return on equity is 3.5% and its return on capital employed is 5.47%.
Does Valiant Organics pay a dividend?
Valiant Organics's dividend yield is 0% at the current price; see the Valiant Organics dividends page for past payouts.
Which sector does Valiant Organics belong to?
Valiant Organics is in the Chemicals & Petrochemicals sector. Its peer comparison and sector ranking are on this page.
What did Valiant Organics's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Valiant Organics's management.
How does Arthneeti AI analyse Valiant Organics?
Arthneeti reads Valiant Organics's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…
